Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij Scalda & Bohn Stafleu van Loghum

Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.

» Andere revante producten voor Scalda studenten en medewerkers.

Registreer

Schaf de BSL Academy aan: 

BSL Academy mbo AG

Eenmaal aangeschaft kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Heb je een vraag, neem dan contact op met Jan van der Velden.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research
Gepubliceerd in:

01-08-2013

Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia

Auteurs: Negin Hadi, Alireza Aminsharifi, Ali Sadeghi, Ali Tourchi

Gepubliceerd in: Quality of Life Research | Uitgave 6/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

We prospectively evaluated the impact of transurethral resection of the prostate (TURP) versus superselective α-adrenergic blocker treatment on health-related quality of life (HRQOL) in men with clinically diagnosed benign prostatic hyperplasia (BPH).

Patients and methods

A total of 219 patients with lower urinary tract symptoms (LUTS) caused by BPH were recruited in this study. Treatment modalities consisted of standard TURP (n = 104) and tamsulosin medical treatment (n = 115). HRQOL was assessed by SF-36-Item Health Survey 1.0. LUTS were estimated by The International Prostate Symptom Score. Patients’ outcome 4 weeks after treatment was compared to pre-treatment status and to that of the other group. Statistically significant changes in each HRQOL scale from baseline to follow-up period were investigated.

Results

Baseline characteristics were similar in both groups except for the duration of disease before treatment that was longer in TURP group. Both treatments resulted in statistically significant improvements from pre-treatment in all scales of QOL after 4 weeks, with no significant differences observed between the two groups. In medical treatment group, there was a significant association between higher educational level and better QOL in all 8 scales. Our outcomes revealed a significant decrease in the IPSS in both groups but this improvement was more evident in TURP group.

Conclusion

All scales concerning HRQOL were favorably improved 4 weeks after both surgical and medical treatment, and no significant differences were observed between these two treatment modalities for patients with symptomatic BPH. This information may aid patients when deciding which treatment option to take.
vorige artikel Impact of nocturnal calf cramping on quality of sleep and health-related quality of life
volgende artikel Perceived health is partially associated with the symptomatological profile in patients with benign and severe conditions: the case of congenital heart disease
Literatuur
1.
Chute, C. G., Panser, L. A., Girman, C. J., et al. (1993). The prevalence of prostatism: A population-based survey of urinary symptoms. Journal of Urology, 150, 85–89.PubMed
2.
Chow, R. D. (2001). Benign prostatic hyperplasia. Patient evaluation and relief of obstructive symptoms. Geriatrics, 56, 33–38.PubMed
3.
Eckhardt, M. D., van Venrooij, G. E., van Melick, H. H., & Boon, T. A. (2001). Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. Journal of Urology, 166, 563–568.PubMedCrossRef
4.
Bruskewitz, R. C. (2003). Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol, 5, 72–80.PubMed
5.
Kaplan, S. A. (2005). Benign prostatic hyperplasia: Patient perceptions and financial reality regarding the aging American prostate. Journal of Urology, 173, 1852.PubMedCrossRef
6.
Arai, Y., Aoki, Y., Okubo, K., et al. (2000). Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: A prospective study. Journal of Urology, 164, 1206–1211.PubMedCrossRef
7.
O’Leary, M. P., Roehrborn, C., Andriole, G., et al. (2003). Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU International, 92, 262–266.PubMedCrossRef
8.
Roehrborn, C. G., Van Kerrebroeck, P., & Nordling, J. (2003). Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU International, 92, 257–261.PubMedCrossRef
9.
Narayan, P., Evans, C. P., & Moon, T. (2003). Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Journal of Urology, 170, 498–502.PubMedCrossRef
10.
Cambio, A. J., & Evans, C. P. (2007). Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Therapeutics and Clinical Risk Management, 3, 181–196.PubMedCrossRef
11.
Suzuki, H., Yano, M., Awa, Y., et al. (2006). Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and rand medical outcomes study 36-item health survey. International Journal of Urology, 13, 1202–1206.PubMedCrossRef
12.
Narayan, P., & Lepor, H. (2001). Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology, 57, 466–470.PubMedCrossRef
13.
Boyd, S. D., & Narayan, P. (1994). Management of benign prostatic hyperplasia. Western Journal of Medicine, 160, 165–166.PubMed
14.
Soderdahl, D. W., Knight, R. W., & Hansberry, K. L. (1996). Erectile dysfunction following transurethral resection of the prostate. Journal of Urology, 156, 1354–1356.PubMedCrossRef
15.
Deliveliotis, C., Liakouras, C., Delis, A., et al. (2004). Prostate operations: Long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population. Urological Research, 32, 283–289.PubMedCrossRef
16.
Ware, J. E., Jr, & Gandek, B. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of Clinical Epidemiology, 51, 903–912.PubMedCrossRef
17.
Montazeri, A., Goshtasebi, A., Vahdaninia, M., & Gandek, B. (2005). The short form health survey (SF-36): Translation and validation study of the Iranian version. Quality of Life Research, 14, 875–882.PubMedCrossRef
18.
Bosch, J. L., Hop, W. C., Kirkels, W. J., & Schroder, F. H. (1995). The international prostate symptom score in a community-based sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. British Journal of Urology, 75, 622–630.PubMedCrossRef
19.
Salinas-Sanchez, A. S., Hernandez-Millan, I., Lorenzo-Romero, J. G., et al. (2001). Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. Quality of Life Research, 10, 543–553.PubMedCrossRef
20.
O’Sullivan, M., Murphy, C., Deasy, C., et al. (2004). Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia. Journal of the American College of Surgeons, 198, 394–403.PubMedCrossRef
21.
Donovan, J. L., Peters, T. J., Neal, D. E., et al. (2000). A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. Journal of Urology, 164, 65–70.PubMedCrossRef
22.
Gacci, M., Bartoletti, R., Figlioli, S., et al. (2003). Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: A prospective study. BJU International, 91, 196–200.PubMedCrossRef
23.
Tascı, A. I., Ilbey, Y. O., Tugcu, V., et al. (2011). Transurethral resection of the prostate with monopolar resectoscope: Single-surgeon experience and long-term results of after 3589 procedures. Urology, 78, 1151–1155.PubMedCrossRef
Metagegevens
Titel
Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia
Auteurs
Negin Hadi
Alireza Aminsharifi
Ali Sadeghi
Ali Tourchi
Publicatiedatum
01-08-2013
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 6/2013
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-012-0259-7

Andere artikelen Uitgave 6/2013

Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards

  • Open Access

Multilevel socioeconomic effects on quality of life in adolescent and young adult survivors of leukemia and lymphoma

Assessment of proximal outcomes of self-management programs: translation and psychometric evaluation of a German version of the Health Education Impact Questionnaire (heiQ™)

Ten-year change in self-rated quality of life in a type 1 diabetes population: Wisconsin Epidemiologic Study of Diabetic Retinopathy

Interpersonal discrimination and health-related quality of life among black and white men and women in the United States

  • Brief Communication

Performance of the parent emotional functioning (PREMO) screener in parents of children undergoing hematopoietic stem cell transplantation

  • Brief Communication